Login to Your Account

Up-and-coming Tapimmune seeks 'more eyes' on I-O assets with uplisting

By Marie Powers
News Editor

Friday, August 12, 2016

Immunotherapy developer Tapimmune Inc., which began life back in 2000 as Genemax Corp., quietly inked a series of deals and kept its head down during the formative years of the I-O field.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription